{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:58:10Z","timestamp":1760147890109,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Background: The Norwegian Cervical Cancer Screening Programme recommends that women treated for cervical intraepithelial neoplasia (CIN) only be returned to 3-year screening after receiving two consecutive negative co-tests, 6 months apart. Here we evaluate adherence to these guidelines and assessed the residual disease, using CIN3+ as the outcome. Methods: This cross-sectional study comprised 1397 women, treated for CIN between 2014 and 2017, who had their cytology, HPV, and histology samples analyzed by a single university department of pathology. Women who had their first and second follow-up at 4\u20138 and 9\u201318 months after treatment were considered adherent to the guidelines. The follow-up ended on 31 December 2021. We used survival analysis to assess the residual and recurrent CIN3 or worse among women with one and two negative co-tests, respectively. Results: 71.8% (1003\/1397) of women attended the first follow-up 4\u20138 months after treatment, and 38.3% were considered adherent at the second follow-up. Nearly 30% of the women had incomplete follow-up at the study end. None of the 808 women who returned to 3-year screening after two negative co-tests were diagnosed with CIN3+, whereas two such cases were diagnosed among the 887 women who had normal cytology\/ASCUS\/LSIL and a negative HPV test at first follow-up (5-year risk of CIN3+: 0.24, 95%, CI: 0.00\u20130.57 per 100 woman-years). Conclusions: The high proportion of women with incomplete follow-up at the end of the study period requires action. The risk of CIN3+ among women with normal cytology\/ASCUS\/LSIL and a negative HPV test at first follow-up is indicative of a return to 3-year screening.<\/jats:p>","DOI":"10.3390\/ijerph20064739","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T02:30:23Z","timestamp":1678242623000},"page":"4739","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["May Women with a Negative Co-Test at First Follow-Up Visit Return to 3-Year Screening after Treatment for Cervical Intraepithelial Neoplasia?"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9875-4991","authenticated-orcid":false,"given":"Finn Egil","family":"Skjeldestad","sequence":"first","affiliation":[{"name":"Research Group Epidemiology of Chronic Diseases, Department of Community Medicine, UiT The Arctic University of Norway, 9037 Troms\u00f8, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8250-3992","authenticated-orcid":false,"given":"Sveinung","family":"Wergeland S\u00f8rbye","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, University Hospital of North Norway, 9038 Troms\u00f8, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"ref_1","unstructured":"D\u00f8rum, A. (2015). Guidelines in Gynecologic Gynecology (in Norwegian), Norwegian Medical Association. Available online: http:\/\/legeforeningen.no\/fagmed\/norsk-gynekologisk-forening\/Veiledere\/Veileder-gynekologisk-onkologi\/."},{"key":"ref_2","unstructured":"Cervixcancer-Prevention (2022, May 08). Nationnelt V\u00e5rdprogram. Chapter 17 Uppf\u00f8ljning Etter Dysplasibehandlng. (Updated 13 April 2021). Available online: https:\/\/kunskapsbanken.cancercentrum.se\/diagnoser\/livmoderhalscancerprevention\/vardprogram\/uppfoljning-efter-dysplasibehandling\/."},{"key":"ref_3","unstructured":"Anderson, L., Pather, S., Wright, G., Hammond, I., and Saville, M. (2022). National Cervical Screening Program: Guidelines for the Management of Screen-Detected Abnormalities, Screening in Specific Populations and Investigation of Abnormal Vaginal Bleeding, Cancer Council. Available online: https:\/\/wiki.cancer.org.au\/australia\/Guidelines:Cervical_cancer\/Screening."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J. Low. Gent. Tract. Dis."},{"key":"ref_5","unstructured":"(2022, May 08). Colposcopic Diagnosis, Treatment and Follow-Up, Cervical Screening: Programme and Colposcoy Mangagement, Available online: https:\/\/www.gov.uk\/government\/publications\/cervical-screening-programme-and-colposcopy-management\/3-colposcopic-diagnosis-treatment-and-follow-up."},{"key":"ref_6","unstructured":"Bjerregard, B., Norrild, B., Nielsen, S., Holten, I., Rygaard, C., and Bro, F. (2012). Screening for Cervical Cancer-Recommendations, Sundhedsstyrelsen. (In Danish)."},{"key":"ref_7","unstructured":"Nieminen, P., Anttila, A., Butzow, R., Hiltunen-Back, E., Jakobsson, M., and Laukkala, T. (2019). Celluarl Changes in the Cervix, Vagina and Vulva, The Finnish Medical Society Duodecim. (In Finnish)."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1002\/ijc.21604","article-title":"Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia","volume":"118","author":"Soutter","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.30623","article-title":"Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review","volume":"141","author":"Hoffman","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_10","unstructured":"(2020, April 04). HPV in Primary Screening. Screening Strategy and National Guidelines. Cervical Cancer Screening. The Norwegian Cancer Registry. 19 May 2019. (In Norwegian)."},{"key":"ref_11","unstructured":"WHO (2020, April 04). The Bethesda System 2001. Cytopathology of the Uterine Cervix-Digital Atlas. International Agency for Research on Cancer. Available online: https:\/\/screening.iarc.fr\/atlasclassifbethesda.php."},{"key":"ref_12","first-page":"301","article-title":"Cervical intraepithelial neoplasia","volume":"8","author":"Richart","year":"1973","journal-title":"Pathol. Annu."},{"key":"ref_13","unstructured":"(2020, April 04). Quality Assurance Manual. Screening Strategy and National Guidelines. Cervical Cancer Screening. The Norwegian Cancer Registry. November 2019. (In Norwegian)."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejogrb.2020.03.022","article-title":"Recurrent disease after treatment for cervical intraepithelial neoplasia-The importance of a flawless definition of residual disease and length of follow-up","volume":"248","author":"Skjeldestad","year":"2020","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/aogs.12116","article-title":"Long-term adherence to follow-up after treatment of cervical intraepithelial neoplasia: Nationwide population-based study","volume":"92","author":"Barken","year":"2013","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/01.AOG.0000278568.29660.9b","article-title":"Compliance after loop electorsurgical excision prcedure or cold knife cone biopsy","volume":"110","author":"Greenspan","year":"2007","journal-title":"Obstet. Gynecol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ygyno.2008.11.022","article-title":"Routine follow-up intervals in patiens with high-grade squamous intraepithelial lesions (HSILO and fre excision margins can safely be increased in the first two years after large loop excision of the transformation zone (LLETS)","volume":"113","author":"Eijsink","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejogrb.2006.05.020","article-title":"Follow-up of screening patients conservatively treated for cervical intraepithelial neoplasia grade 2\u20133","volume":"133","author":"Cristiani","year":"2007","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/ajo.12309","article-title":"The human papillomavirus Test of Cure: A lesson on compliance with the NHMRC guidelines on screening to prevent cervical cancer","volume":"55","author":"Munro","year":"2015","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0029-7844(97)00276-7","article-title":"Residual and recurrent disease after laser conization for cervical intraepithelial neoplasia","volume":"90","author":"Skjeldestad","year":"1997","journal-title":"Obstet. Gynecol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S1470-2045(17)30700-3","article-title":"Incomplete excision of cervical precancer as a predictor treatment failure: A systematic review and meta-analysis","volume":"18","author":"Arbyn","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/LGT.0000000000000529","article-title":"Risk estimates supporting the 2019 ASCC Risk-Based Management Consensus Guidelines","volume":"24","author":"Egemen","year":"2020","journal-title":"J. Low. Genit. Tract. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/LGT.0000000000000528","article-title":"A 2019 ASCCP Risk-Based Management Consensus Guidelines: Methods for risk estimation, recommended management, and validation","volume":"24","author":"Cheung","year":"2020","journal-title":"J. Low. Genit. Tract. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/LGT.0000000000000530","article-title":"A study of partial human papillomavirus genotyping in support of the 2019 ASCCP risk-based management consensus guidelines","volume":"24","author":"Demarco","year":"2020","journal-title":"J. Low. Genit. Tract. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1470-2045(11)70078-X","article-title":"Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: A long-term multi-cohort study","volume":"12","author":"Kocken","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_26","first-page":"927","article-title":"Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication","volume":"128","author":"Li","year":"2010","journal-title":"IJC"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/6\/4739\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:50:32Z","timestamp":1760122232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/6\/4739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijerph20064739"],"URL":"https:\/\/doi.org\/10.3390\/ijerph20064739","relation":{},"ISSN":["1660-4601"],"issn-type":[{"type":"electronic","value":"1660-4601"}],"subject":[],"published":{"date-parts":[[2023,3,8]]}}}